Greeff K, Fox A A
Basic Res Cardiol. 1984;79 Suppl:16-20. doi: 10.1007/978-3-642-72376-6_3.
The sodium/potassium-ATPase complex is, according to modern research, the binding site for cardiac glycosides on the outer surface of the cell membrane and their receptor. Inhibition of this enzyme by cardiac glycosides leads for instance in the heart to a decrease or a delay in membrane sodium/potassium-ion transport, and indirectly to an increase in the intracellular ionized calcium-concentration and an increase in cardiac contractile force. According to recent observations the activity of the sodium/potassium-ATPase or its concentration, and therefore the concentration of binding sites can increase in some tissues after long term treatment with cardiac glycosides. This might explain the occasionally observed tolerance to digitalis glycosides.
根据现代研究,钠/钾-ATP酶复合物是细胞膜外表面上强心苷及其受体的结合位点。强心苷对该酶的抑制作用,例如在心脏中会导致膜钠/钾离子转运减少或延迟,并间接导致细胞内离子钙浓度增加和心脏收缩力增强。根据最近的观察结果,长期使用强心苷治疗后,某些组织中钠/钾-ATP酶的活性或其浓度,以及因此结合位点的浓度可能会增加。这可能解释了偶尔观察到的对洋地黄苷的耐受性。